URB-597结构式
|
常用名 | URB-597 | 英文名 | URB597 |
---|---|---|---|---|
CAS号 | 546141-08-6 | 分子量 | 338.400 | |
密度 | 1.2±0.1 g/cm3 | 沸点 | 533.2±50.0 °C at 760 mmHg | |
分子式 | C20H22N2O3 | 熔点 | N/A | |
MSDS | 中文版 美版 | 闪点 | 276.3±30.1 °C | |
符号 |
GHS07, GHS09 |
信号词 | Warning |
URB-597用途URB597是口服生物相容性的FAAH抑制剂,IC50为4.6 nM,对其它的cannabinoid-相关靶点无活性。 |
中文名 | 3'-氨基甲酰-[1,1'-联苯]-3-基环己基氨基甲酸酯 |
---|---|
英文名 | 3'-Carbamoyl-[1,1'-biphenyl]-3-yl cyclohexylcarbamate |
中文别名 | 东凌草素 | 3'-胺甲酰基联苯-3-基环己基氨基甲酸甲酯 | 3'-胺甲酰基联苯-3-基环己基氨基甲酸酯 | N-环己基氨基甲酸 3'-(氨基甲酰基)[1,1'-联苯]-3-基酯 |
英文别名 | 更多 |
描述 | URB597是口服生物相容性的FAAH抑制剂,IC50为4.6 nM,对其它的cannabinoid-相关靶点无活性。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.2±0.1 g/cm3 |
---|---|
沸点 | 533.2±50.0 °C at 760 mmHg |
分子式 | C20H22N2O3 |
分子量 | 338.400 |
闪点 | 276.3±30.1 °C |
精确质量 | 338.163055 |
PSA | 81.42000 |
LogP | 3.51 |
外观性状 | powder | white |
蒸汽压 | 0.0±1.4 mmHg at 25°C |
折射率 | 1.618 |
储存条件 | 2-8°C |
水溶解性 | DMSO: ~14 mg/mL, soluble |
符号 |
GHS07, GHS09 |
---|---|
信号词 | Warning |
危害声明 | H319-H410 |
警示性声明 | P273-P305 + P351 + P338-P501 |
个人防护装备 | Eyeshields;Gloves |
危害码 (欧洲) | N |
风险声明 (欧洲) | 50/53 |
安全声明 (欧洲) | 22-24/25-60-61 |
危险品运输编码 | UN 3077 9/PG 3 |
WGK德国 | 3 |
海关编码 | 2924299090 |
海关编码 | 2924299090 |
---|---|
中文概述 | 2924299090. 其他环酰胺(包括环氨基甲酸酯)(包括其衍生物以及他们的盐). 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0% |
申报要素 | 品名, 成分含量, 用途, 包装 |
Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Neurobiol. Dis. 74 , 295-304, (2015) Long-term administration of l-3,4-dihydroxyphenylalanine (levodopa), the mainstay treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of action and motor complicatio... |
|
Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies.
Neurobiol. Dis. 79 , 41-50, (2015) Anandamide (AEA) is an endocannabinoid (EC) that modulates multiple functions in the CNS and that is released in areas of injury, exerting putative neuroprotective actions. In the present study, we ha... |
|
Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: from ultrapotent to hyperpotent.
Biochem. Pharmacol. 92(4) , 669-89, (2014) Besides the suggested role of a putative endocannabinoid membrane transporter mediating the cellular uptake of the endocannabinoid anandamide (AEA), this process is intrinsically coupled to AEA degrad... |
cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester |
URB597 |
3'-Carbamoyl-3-biphenylyl cyclohexylcarbamate |
Carbamic acid, N-cyclohexyl-, 3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl ester |
3'-Carbamoylbiphenyl-3-yl cyclohexylcarbamate |
Cyclohexyl-carbamic acid 3'-carbamoyl-biphenyl-3-yl ester |
[3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate |
3'-(aminocarbonyl)-1,1'-biphenyl-3-yl cyclohexylcarbamate |
URB-597 |